The European medical regulatory landscape is undergoing its most significant overhaul in years. The eagerly-awaited Medical Device Regulation (MDR), published in May 2017, will bring substantial changes to the way medical device manufacturers bring their devices into the European market.
The EU Medical Device Regulation (MDR) was officially passed in May 2017 and manufacturers have until 2020, to be fully compliant with all changes set forth within the new regulation. View this 30 min. webinar to better understand the changes that clinical teams should prepare for now to be successful under the new regulation.
FDA medical device regulators’ top priorities over the next three years include improving employee engagement, increasing simplicity and building collaborative communities, according to a new Strategic Priorities paper that FDA’s CDRH released today.
The FDA is planning a new “super office” for its Center for Devices and Radiological Health department and the soon-to-be created Office of Product Evolution and Quality, according to a Regulatory Affairs Professionals Society report.
The U.S. House of Representatives voted 283-132 this week to repeal the 2.3% tax levied upon medical devices as part of the Affordable Care Act.
The UK’s Medicines and Healthcare products Regulatory Agency (MHRA) released today a business plan for the upcoming year, noting its primary focus on developing a consensus around a proposed model for the future of the country’s regulation of medicines and medical devices following its departure from the EU.
The General Data Protection Regulation or GDPR is effective as of 25 May 2018 and it will bring substantial changes to the way medical device manufacturers and sponsors will collect and process personal data, including data concerning health.
China plans to accept data from foreign clinical trials in its medical device approval process if the device is already approved overseas.
The final texts of the new European medical device and in vitro diagnostic (IVD) regulations were published today in the Official Journal of the European Union, setting in motion the timeline for implementation of the new regulations to commence on 25 May.
The FDA proposes a rule that would amend regulations regarding the classification of products as biological products, devices, drugs or combination products.